Hong P Xie

US Patent:

20200384006, Dec 10, 2020

Filed:

Jun 5, 2020

Appl. No.:

16/893477

Inventors:

- Beerse, BE
Kathryn Elizabeth Packman - Newton MA, US
Nahor Haddish-Berhane - Doylestown PA, US
Geert S.J. Mannens - Lier, BE
Junguo Zhou - Flemington NJ, US
Anthony T. Greway - Bound Brook NJ, US
Dirk Brehmer - Freiburg, DE
Yue Guo - North Wales PA, US
Tongfei Wu - Hever, BE
Hong Xie - Dresher PA, US
Josh Lauring - Towson MD, US

International Classification:

A61K 31/7064
A61P 35/04

Abstract:

The present disclosure provides methods for treating a human patient diagnosed with a cancer, comprising administering a therapeutically effective amount of a PRMT5 (protein arginine methyltransferase 5) inhibitor, certain methods comprising (i) administering to the patient initial doses of at least about 0.1 mg per day of the PRMT5 inhibitor that is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharmaceutically acceptable addition salt or solvate thereof for an initial dosing period of about 5 to about 21 days; and (ii) administering to the patient subsequent doses of at least about 0.1 mg per day of the PRMT5 inhibitor for one or more subsequent dosing periods of about 5 to about 21 days each. In these methods, a first subsequent dosing period is separated in time from the initial dosing period by at least about 5 days and the subsequent dosing periods are separated in time from each other by at least about 5 days.